全文获取类型
收费全文 | 4020篇 |
免费 | 298篇 |
国内免费 | 21篇 |
专业分类
耳鼻咽喉 | 24篇 |
儿科学 | 125篇 |
妇产科学 | 74篇 |
基础医学 | 585篇 |
口腔科学 | 78篇 |
临床医学 | 461篇 |
内科学 | 816篇 |
皮肤病学 | 118篇 |
神经病学 | 368篇 |
特种医学 | 121篇 |
外科学 | 386篇 |
综合类 | 19篇 |
一般理论 | 1篇 |
预防医学 | 393篇 |
眼科学 | 106篇 |
药学 | 247篇 |
中国医学 | 12篇 |
肿瘤学 | 405篇 |
出版年
2024年 | 7篇 |
2023年 | 42篇 |
2022年 | 92篇 |
2021年 | 142篇 |
2020年 | 86篇 |
2019年 | 138篇 |
2018年 | 119篇 |
2017年 | 98篇 |
2016年 | 115篇 |
2015年 | 113篇 |
2014年 | 149篇 |
2013年 | 222篇 |
2012年 | 309篇 |
2011年 | 317篇 |
2010年 | 162篇 |
2009年 | 140篇 |
2008年 | 268篇 |
2007年 | 224篇 |
2006年 | 243篇 |
2005年 | 252篇 |
2004年 | 199篇 |
2003年 | 197篇 |
2002年 | 190篇 |
2001年 | 37篇 |
2000年 | 19篇 |
1999年 | 43篇 |
1998年 | 39篇 |
1997年 | 34篇 |
1996年 | 33篇 |
1995年 | 27篇 |
1994年 | 17篇 |
1993年 | 11篇 |
1992年 | 15篇 |
1991年 | 8篇 |
1990年 | 9篇 |
1989年 | 8篇 |
1988年 | 12篇 |
1987年 | 9篇 |
1986年 | 10篇 |
1985年 | 11篇 |
1984年 | 12篇 |
1983年 | 9篇 |
1982年 | 11篇 |
1981年 | 16篇 |
1980年 | 15篇 |
1979年 | 10篇 |
1978年 | 7篇 |
1977年 | 7篇 |
1971年 | 6篇 |
1958年 | 5篇 |
排序方式: 共有4339条查询结果,搜索用时 0 毫秒
991.
992.
Melinda A. Engevik Beatrice Herrmann Wenly Ruan Amy C. Engevik Kristen A. Engevik Faith Ihekweazu Zhongcheng Shi Berkley Luck Alexandra L. Chang-Graham Magdalena Esparza Susan Venable Thomas D. Horvath Sigmund J. Haidacher Kathleen M. Hoch Anthony M. Haag Deborah A. Schady Joseph M. Hyser Jennifer K. Spinler James Versalovic 《Gut microbes》2021,13(1)
993.
Hanieh Ghassabian Federico Falchi Martina Timmoneri Beatrice Mercorelli Arianna Loregian Giorgio Pal Gualtiero Alvisi 《Viruses》2021,13(5)
Human cytomegalovirus (HCMV) is a leading cause of severe diseases in immunocompromised individuals, including AIDS patients and transplant recipients, and in congenitally infected newborns. The utility of available drugs is limited by poor bioavailability, toxicity, and emergence of resistant strains. Therefore, it is crucial to identify new targets for therapeutic intervention. Among the latter, viral protein–protein interactions are becoming increasingly attractive. Since dimerization of HCMV DNA polymerase processivity factor ppUL44 plays an essential role in the viral life cycle, being required for oriLyt-dependent DNA replication, it can be considered a potential therapeutic target. We therefore performed an in silico screening and selected 18 small molecules (SMs) potentially interfering with ppUL44 homodimerization. Antiviral assays using recombinant HCMV TB4-UL83-YFP in the presence of the selected SMs led to the identification of four active compounds. The most active one, B3, also efficiently inhibited HCMV AD169 strain in plaque reduction assays and impaired replication of an AD169-GFP reporter virus and its ganciclovir-resistant counterpart to a similar extent. As assessed by Western blotting experiments, B3 specifically reduced viral gene expression starting from 48 h post infection, consistent with the inhibition of viral DNA synthesis measured by qPCR starting from 72 h post infection. Therefore, our data suggest that inhibition of ppUL44 dimerization could represent a new class of HCMV inhibitors, complementary to those targeting the DNA polymerase catalytic subunit or the viral terminase complex. 相似文献
994.
Ferri Gianmarco Corradini Beatrice Gianfreda Denise Ferrari Francesca Silingardi Enrico 《International journal of legal medicine》2022,136(5):1255-1260
International Journal of Legal Medicine - The availability of a reliable molecular assay in species recognition in forensic cases is of paramount importance when visual inspection or morphological... 相似文献
995.
996.
997.
Cristina Grippaudo Concetta Cafiero Isabella D'Apolito Beatrice Ricci Sylvia A. Frazier-Bowers 《The Angle orthodontist》2018,88(3):275
Objective:To test the hypothesis that mutations in the parathyroid hormone 1 receptor (PTH1R) include effects in both primary and permanent teeth.Materials and Methods:DNA was extracted from saliva samples of 29 patients (8 familial and 21 sporadic) who presented with clinical evidence of infraoccluded teeth, and their unaffected relatives (N = 22). Sequencing followed by mutational analysis of the coding regions of PTH1R gene was completed for all individuals (N = 29).Results:Eight of 29 cases revealed a heterozygous pathogenic variant in the PTH1R gene; five of eight variants represented distinct mutations based on comparison with the dbSNP, HGMD, and ESP databases. One mutation (c.1765 T>C p.Trp89Arg) was found to segregate within a family (n = 3). In silico analyses for all variants revealed a putative pathogenic effect. A genotype-phenotype correlation was reported as defined by a functional mutation in PTH1R and corresponding effects on one or more posterior teeth only; unilateral or bilateral involvement, infraoccluded primary teeth.Conclusions:Novel mutations were reported in the PTH1R gene that included PFE-affected primary molars, thus providing the basis for using a genetic diagnostic tool for early diagnosis leading to proper management. 相似文献
998.
Kazuhiro Tanaka Takashi Sasayama Yasuhiro Irino Kumi Takata Hiroaki Nagashima Naoko Satoh Katsusuke Kyotani Takashi Mizowaki Taichiro Imahori Yasuo Ejima Kenta Masui Beatrice Gini Huijun Yang Kohkichi Hosoda Ryohei Sasaki Paul S. Mischel Eiji Kohmura 《The Journal of clinical investigation》2015,125(4):1591-1602
The mechanistic target of rapamycin (mTOR) is hyperactivated in many types of cancer, rendering it a compelling drug target; however, the impact of mTOR inhibition on metabolic reprogramming in cancer is incompletely understood. Here, by integrating metabolic and functional studies in glioblastoma multiforme (GBM) cell lines, preclinical models, and clinical samples, we demonstrate that the compensatory upregulation of glutamine metabolism promotes resistance to mTOR kinase inhibitors. Metabolomic studies in GBM cells revealed that glutaminase (GLS) and glutamate levels are elevated following mTOR kinase inhibitor treatment. Moreover, these mTOR inhibitor–dependent metabolic alterations were confirmed in a GBM xenograft model. Expression of GLS following mTOR inhibitor treatment promoted GBM survival in an α-ketoglutarate–dependent (αKG-dependent) manner. Combined genetic and/or pharmacological inhibition of mTOR kinase and GLS resulted in massive synergistic tumor cell death and growth inhibition in tumor-bearing mice. These results highlight a critical role for compensatory glutamine metabolism in promoting mTOR inhibitor resistance and suggest that rational combination therapy has the potential to suppress resistance. 相似文献
999.
Giuseppe Nardi Vanessa Agostini Beatrice Rondinelli Emanuele Russo Barbara Bastianini Giovanni Bini Simona Bulgarelli Emiliano Cingolani Alessia Donato Giorgio Gambale Giulia Ranaldi 《Critical care (London, England)》2015,19(1)
IntroductionHemorrhage is the principal cause of death in the first few hours following severe injury. Coagulopathy is a frequent complication of critical bleeding. A network of Italian trauma centers recently developed a protocol to prevent and treat trauma-induced coagulopathy. A pre-post cohort multicenter study was conducted to assess the impact of the early coagulation support (ECS) protocol on blood products consumption, mortality and treatment costs.MethodsWe prospectively collected data from all severely injured patients (Injury Severity Score (ISS) >15) admitted to two trauma centers in 2013 and compared these findings with the data for 2011. Patients transfused with at least 3 units of packed red blood cells (PRBCs) within 24 hours of an accident were included in the study. In 2011, patients with significant hemorrhaging were treated with early administration of plasma with the aim of achieving a high (≥1:2) plasma-to-PRBC ratio. In 2013, the ECS protocol was the treatment strategy. Outcome data, blood product consumption and treatment costs were compared between the two periods.ResultsThe two groups were well matched for demographics, injury severity (ISS: 32.9 in 2011 versus 33.6 in 2013) and clinical and laboratory data on admission. In 2013, a 40% overall reduction in PRBCs was observed, together with a 65% reduction in plasma and a 52% reduction in platelets. Patients in the ECS group received fewer blood products: 6.51 units of PRBCs versus 8.14 units. Plasma transfusions decreased from 8.98 units to 4.21 units (P <0.05), and platelets fell from 4.14 units to 2.53 units (P <0.05). Mortality in 2013 was 13.5% versus 20% in 2011 (13 versus 26 hospital deaths, respectively) (nonsignificant). When costs for blood components, factors and point-of-care tests were compared, a €76,340 saving in 2013 versus 2011 (23%) was recorded.ConclusionsThe introduction of the ECS protocol in two Italian trauma centers was associated with a marked reduction in blood product consumption, reaching statistical significance for plasma and platelets, and with a non-significant trend toward a reduction in early and 28-day mortality. The overall costs for transfusion and coagulation support (including point-of-care tests) decreased by 23% between 2011 and 2013. 相似文献
1000.
Andrea Endimiani Francesco Luzzaro Beatrice Pini Gianfranco Amicosante Gian Maria Rossolini Antonio Q Toniolo 《BMC infectious diseases》2006,6(1):52